BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30413648)

  • 1. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
    Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
    Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody.
    Staudacher AH; Liapis V; Tieu W; Wittwer NL; Brown MP
    J Control Release; 2020 Nov; 327():779-787. PubMed ID: 32946876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.
    Staudacher AH; Liapis V; Wittwer NL; Tieu W; Lam HC; Leusen J; Brown MP
    Biomed Pharmacother; 2022 Jul; 151():113090. PubMed ID: 35567988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
    Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
    PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
    Al-Ejeh F; Staudacher AH; Smyth DR; Darby JM; Denoyer D; Tsopelas C; Hicks RJ; Brown MP
    J Nucl Med; 2014 May; 55(5):772-9. PubMed ID: 24676755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
    Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
    Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
    Staudacher AH; Brown MP
    Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
    Al-Ejeh F; Darby JM; Brown MP
    PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates.
    Li F; Ulrich M; Jonas M; Stone IJ; Linares G; Zhang X; Westendorf L; Benjamin DR; Law CL
    Mol Cancer Ther; 2017 Jul; 16(7):1347-1354. PubMed ID: 28341790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
    Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
    J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence.
    Gong X; Azhdarinia A; Ghosh SC; Xiong W; An Z; Liu Q; Carmon KS
    Mol Cancer Ther; 2016 Jul; 15(7):1580-90. PubMed ID: 27207778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
    Liapis V; Tieu W; Wittwer NL; Gargett T; Evdokiou A; Takhar P; Rudd SE; Donnelly PS; Brown MP; Staudacher AH
    Mol Imaging Biol; 2021 Dec; 23(6):914-928. PubMed ID: 34231102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
    Singh AP; Sharma S; Shah DK
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
    Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
    Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.
    Del Solar V; Contel M
    J Inorg Biochem; 2019 Oct; 199():110780. PubMed ID: 31434020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
    Staudacher AH; Al-Ejeh F; Fraser CK; Darby JM; Roder DM; Ruszkiewicz A; Manavis J; Brown MP
    EJNMMI Res; 2014 Jan; 4(1):2. PubMed ID: 24387284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.